KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vir Biotechnology (VIR) EBIT Margin (2018 - 2025)

Vir Biotechnology's EBIT Margin history spans 8 years, with the latest figure at 74.79% for Q4 2025.

  • For Q4 2025, EBIT Margin rose 87195.0% year-over-year to 74.79%; the TTM value through Dec 2025 reached 699.18%, up 14531.0%, while the annual FY2025 figure was 699.18%, 9210.0% up from the prior year.
  • EBIT Margin for Q4 2025 was 74.79% at Vir Biotechnology, up from 72267.92% in the prior quarter.
  • Across five years, EBIT Margin topped out at 82.26% in Q1 2022 and bottomed at 72267.92% in Q3 2025.
  • The 5-year median for EBIT Margin is 691.23% (2022), against an average of 6258.79%.
  • The largest annual shift saw EBIT Margin soared 811025bps in 2022 before it tumbled -6254926bps in 2025.
  • A 5-year view of EBIT Margin shows it stood at 69.6% in 2021, then tumbled by -538bps to 304.6% in 2022, then plummeted by -172bps to 828.12% in 2023, then fell by -14bps to 946.74% in 2024, then surged by 92bps to 74.79% in 2025.
  • Per Business Quant, the three most recent readings for VIR's EBIT Margin are 74.79% (Q4 2025), 72267.92% (Q3 2025), and 9754.28% (Q2 2025).